|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||||
 Fundamental & Clinical PharmacologyVolume 19 Issue 4, Pages 421 - 427 Published Online: 27 Jun 2005 Journal compilation © 2010 Société Française de Pharmacologie et de Thérapeutique Published on behalf of the Société Française de Pharmacologie et de Thérapeutique
Abstract | References | Full Text: HTML, PDF (Size: 79K) | Related Articles | Citation Tracking  REVIEW ARTICLE Eradication of Helicobacter pylori: recent advances in treatment Copyright 2005 Blackwell Publishing KEYWORDS eradication •
H. pylori
Abstract
Helicobacter pylori plays a key role in dyspepsia, peptic ulcer disease, and gastric neoplasia and eradication of the infection has become an important treatment goal in clinical practice. Seven-day proton-pump inhibitor–amoxicillin–clarithromycin triple therapy is the current first-line therapy for H. pylori but eradication rates are compromised by poor compliance and antibiotic resistance. Ten-day sequential treatment may emerge as an alternative first-line therapy. Bismuth-based quadruple therapy is the second-line regimen of choice. Antimicrobial sensitivity testing is not recommended in the routine management of H. pylori infection. Novel triple-therapy regimens containing rifabutin, levofloxacin, or furazolidone may be useful alternatives as second- or third-line therapy. Received 30 August 2004; revised 11 February 2005; accepted 8 March 2005 | 
|
